Incyte sees FY25 net product revenue $4.23B-$4.32B

The company said, “Incyte’s (INCY) guidance for the fiscal year 2025 is summarized below. Incyte is raising its full year 2025 net product revenue guidance to $4.23 – $4.32 billion to account for higher demand for Jakafi and other hematology and oncology marketed products. The update includes raised guidance for Jakafi to $3.050 – $3.075 billion, as well as other hematology and oncology marketed products to $550 – $575 million. Incyte is reaffirming its guidance across all other categories.”